Nanjing Hencer Pharmacy Co. Ltd.

Primary purpose: To preliminarily evaluate the pharmacokinetic (PK) characteristics of JMX-2006 for injection and single subcutaneous injection of Norad®. Secondary purpose: To preliminarily evaluate the pharmacodynamic (PD) characteristics of JMX-2006 for injection and Norad® after single administration; To preliminarily evaluate the safety and tolerability of JMX-2006 for injection and Norad® after single administration.

A single-center, randomized, open, two-period crossover, single oral trial design was used to compare the differences in absorption extent and absorption rate between the oro-disintegrating tablets (80 mg) of phloroglucinol produced by Nanjing Hengsheng Pharmaceutical Co., Ltd. and the phloroglucinol oral lyophilized tablets (specification: 80 mg) originally developed by Teva Sante and marketed in France under fasting and postprandial administration conditions in healthy Chinese people, and to evaluate the safety of the oro-disintegrating tablets of phloroglucinol produced by Nanjing Hengsheng Pharmaceutical Co., Ltd.

A single-center, randomized, open-label, four-period, completely repeated crossover, single-dose fasting and postprandial administration trial design was used to evaluate the bioequivalence of avatrombopag maleate tablets (specification: 20 mg) produced by Nanjing Hengsheng Pharmaceutical Co., Ltd. and avatrombopag maleate tablets (trade name: Doptelet®/Su Kexin®, specification: 20 mg) certified by AkaRx Inc. in healthy Chinese people when taken orally on an empty stomach and after a meal, to provide evidence for the consistency of clinical efficacy between avatrombopag maleate tablets produced by Nanjing Hengsheng Pharmaceutical Co., Ltd. and avatrombopag maleate tablets certified by AkaRx Inc.